Neurocrine Biosciences (NBIX) Revenue Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -0.81% |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | -0.24% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 0.07% |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | -1.92% |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 4.88% |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 39.49% |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 10.23% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | 26.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.49% |
| Mar 31, 2026 | 42.25% |
| Dec 31, 2025 | 28.33% |
| Sep 30, 2025 | 27.78% |
| Jun 30, 2025 | 16.49% |
| Mar 31, 2025 | 11.12% |
| Dec 31, 2024 | 21.84% |
| Sep 30, 2024 | 24.72% |
| Jun 30, 2024 | 30.37% |
| Mar 31, 2024 | 22.57% |
| Dec 31, 2023 | 25.05% |
| Sep 30, 2023 | 28.59% |
| Jun 30, 2023 | 2,163.50% |
| Mar 31, 2023 | 35.35% |
| Dec 31, 2022 | 32.05% |
| Sep 30, 2022 | 31.05% |
| Jun 30, 2022 | -93.08% |
| Mar 31, 2022 | 31.28% |
| Dec 31, 2021 | 25.86% |
| Sep 30, 2021 | 14.51% |